Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

137 Results

Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
AQ
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
AQ
Transcript : Atea Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
AQ
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
AQ
Transcript : Atea Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Transcript : Atea Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
AQ
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
AQ
Transcript : Atea Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
AQ
Transcript : Atea Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
AQ
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
AQ
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
AQ
Transcript : Atea Pharmaceuticals, Inc., Q1 2023 Earnings Call, May 08, 2023
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
AQ
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
AQ
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases
AQ
Atea Pharmaceuticals : Low Risk of Drug-Drug Interactions (DDIs) for Bemnifosbuvir (BEM) Based Upon In Vitro Metabolism and Transporter Interaction Studies
PU
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research
AQ
Transcript : Atea Pharmaceuticals, Inc., Q4 2022 Earnings Call, Feb 28, 2023
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
AQ
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
AQ
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
AQ
Transcript : Atea Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 03:00 PM
Atea Pharmaceuticals Highlights Strategic Priorities for 2023
AQ
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
AQ
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
AQ
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
AQ
Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
AQ
Transcript : Atea Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 07, 2022
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
AQ
Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
AQ
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue
AQ
Transcript : Atea Pharmaceuticals, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 12:55 PM
Transcript : Atea Pharmaceuticals, Inc. - Special Call
Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19
AQ
Atea Pharmaceuticals Announces Upcoming Investor Events
AQ
Atea Pharmaceuticals : Reports Second Quarter 2022 Financial Results and Provides Business Update - Form 8-K
PU
Transcript : Atea Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 08, 2022
Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
AQ
Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference
AQ
Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
AQ
KEZAR LIFE SCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
Kezar Life Sciences, Inc. Announces Executive Changes
CI
No results for this search
  1. Stock Market
  2. Advanced search
  3. Jean-Pierre Sommadossi
  4. News